Hilda E Ghadieh1, Lucia Russo2, Harrison T Muturi3, Simona S Ghanem2, Iyad H Manaserh2, Hye Lim Noh4, Sujin Suk4, Jason K Kim5, Jennifer W Hill2, Sonia M Najjar6. 1. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA; Center for Diabetes and Endocrine Research, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA. 2. Center for Diabetes and Endocrine Research, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA. 3. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA. 4. Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. 5. Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA; Division of Endocrinology, Metabolism and Diabetes, University of Massachusetts Medical School, Worcester, MA, USA. 6. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA; Center for Diabetes and Endocrine Research, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA; Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA. Electronic address: najjar@ohio.edu.
Abstract
BACKGROUND: CEACAM1 regulates insulin sensitivity by promoting insulin clearance. Accordingly, global C57BL/6J.Cc1-/- null mice display hyperinsulinemia due to impaired insulin clearance at 2 months of age, followed by insulin resistance, steatohepatitis, visceral obesity and leptin resistance at 6 months. The study aimed at investigating the primary role of hepatic CEACAM1 in insulin and lipid homeostasis independently of its metabolic effect in extra-hepatic tissues. METHODS: Liver-specific C57BL/6J.AlbCre+Cc1fl/fl mice were generated and their metabolic phenotype was characterized by comparison to that of their littermate controls at 2-9 months of age, using hyperinsulinemic-euglycemic clamp analysis and indirect calorimetry. The effect of hyperphagia on insulin resistance was assessed by pair-feeding experiments. RESULTS: Liver-specific AlbCre+Cc1fl/fl mutants exhibited impaired insulin clearance and hyperinsulinemia at 2 months, followed by hepatic insulin resistance (assessed by hyperinsulinemic-euglycemic clamp analysis) and steatohepatitis at ~ 7 months of age, at which point visceral obesity and hyperphagia developed, in parallel to hyperleptinemia and blunted hypothalamic STAT3 phosphorylation in response to an intraperitoneal injection of leptin. Hyperinsulinemia caused hypothalamic insulin resistance, followed by increased fatty acid synthase activity, which together with defective hypothalamic leptin signaling contributed to hyperphagia and reduced physical activity. Pair-feeding experiment showed that hyperphagia caused systemic insulin resistance, including blunted insulin signaling in white adipose tissue and lipolysis, at 8-9 months of age. CONCLUSION: AlbCre+Cc1fl/fl mutants provide an in vivo demonstration of the key role of impaired hepatic insulin clearance and hyperinsulinemia in the pathogenesis of secondary hepatic insulin resistance independently of lipolysis. They also reveal an important role for the liver-hypothalamic axis in the regulation of energy balance and subsequently, systemic insulin sensitivity.
BACKGROUND:CEACAM1 regulates insulin sensitivity by promoting insulin clearance. Accordingly, global C57BL/6J.Cc1-/- null mice display hyperinsulinemia due to impaired insulin clearance at 2 months of age, followed by insulin resistance, steatohepatitis, visceral obesity and leptin resistance at 6 months. The study aimed at investigating the primary role of hepatic CEACAM1 in insulin and lipid homeostasis independently of its metabolic effect in extra-hepatic tissues. METHODS: Liver-specific C57BL/6J.AlbCre+Cc1fl/fl mice were generated and their metabolic phenotype was characterized by comparison to that of their littermate controls at 2-9 months of age, using hyperinsulinemic-euglycemic clamp analysis and indirect calorimetry. The effect of hyperphagia on insulin resistance was assessed by pair-feeding experiments. RESULTS: Liver-specific AlbCre+Cc1fl/fl mutants exhibited impaired insulin clearance and hyperinsulinemia at 2 months, followed by hepatic insulin resistance (assessed by hyperinsulinemic-euglycemic clamp analysis) and steatohepatitis at ~ 7 months of age, at which point visceral obesity and hyperphagia developed, in parallel to hyperleptinemia and blunted hypothalamicSTAT3 phosphorylation in response to an intraperitoneal injection of leptin. Hyperinsulinemia caused hypothalamic insulin resistance, followed by increased fatty acid synthase activity, which together with defective hypothalamic leptin signaling contributed to hyperphagia and reduced physical activity. Pair-feeding experiment showed that hyperphagia caused systemic insulin resistance, including blunted insulin signaling in white adipose tissue and lipolysis, at 8-9 months of age. CONCLUSION: AlbCre+Cc1fl/fl mutants provide an in vivo demonstration of the key role of impaired hepatic insulin clearance and hyperinsulinemia in the pathogenesis of secondary hepatic insulin resistance independently of lipolysis. They also reveal an important role for the liver-hypothalamic axis in the regulation of energy balance and subsequently, systemic insulin sensitivity.
Authors: P R Patel; S K Ramakrishnan; M K Kaw; C K Raphael; S Ghosh; J S Marino; G Heinrich; S J Lee; R E Bourey; J W Hill; D Y Jung; D A Morgan; J K Kim; K Rahmouni; S K Rahmouni; S M Najjar Journal: Diabetologia Date: 2011-12-11 Impact factor: 10.122
Authors: Matthew J Westacott; Nikki L Farnsworth; Joshua R St Clair; Greg Poffenberger; Audrey Heintz; Nurin W Ludin; Nathaniel J Hart; Alvin C Powers; Richard K P Benninger Journal: Diabetes Date: 2017-06-06 Impact factor: 9.461
Authors: Aleksey V Matveyenko; David Liuwantara; Tatyana Gurlo; David Kirakossian; Chiara Dalla Man; Claudio Cobelli; Morris F White; Kyle D Copps; Elena Volpi; Satoshi Fujita; Peter C Butler Journal: Diabetes Date: 2012-06-11 Impact factor: 9.461
Authors: Mashani Mohamad; Sarah Jayne Mitchell; Lindsay Edward Wu; Melanie Yvonne White; Stuart James Cordwell; John Mach; Samantha Marie Solon-Biet; Dawn Boyer; Dawn Nines; Abhirup Das; Shi-Yun Catherine Li; Alessandra Warren; Sarah Nicole Hilmer; Robin Fraser; David Andrew Sinclair; Stephen James Simpson; Rafael de Cabo; David George Le Couteur; Victoria Carroll Cogger Journal: Aging Cell Date: 2016-04-20 Impact factor: 9.304
Authors: Raghd Abu Helal; Harrison T Muturi; Abraham D Lee; Wei Li; Hilda E Ghadieh; Sonia M Najjar Journal: Int J Mol Sci Date: 2022-04-14 Impact factor: 6.208
Authors: Jehnan Liu; Harrison T Muturi; Saja S Khuder; Raghd Abu Helal; Hilda E Ghadieh; Sadeesh K Ramakrishnan; Meenakshi K Kaw; Sumona Ghosh Lester; Ahmed Al-Khudhair; Philip B Conran; Khew-Voon Chin; Cara Gatto-Weis; Sonia M Najjar Journal: Metabolism Date: 2020-03-21 Impact factor: 8.694
Authors: Mujtaba H Shah; Paolo Piaggi; Helen C Looker; Ethan Paddock; Jonathan Krakoff; Douglas C Chang Journal: Diabetologia Date: 2021-01-06 Impact factor: 10.122
Authors: Malcolm A Leissring; Carlos M González-Casimiro; Beatriz Merino; Caitlin N Suire; Germán Perdomo Journal: Int J Mol Sci Date: 2021-02-24 Impact factor: 5.923
Authors: Raghd Abu Helal; Lucia Russo; Hilda E Ghadieh; Harrison T Muturi; Suman Asalla; Abraham D Lee; Cara Gatto-Weis; Sonia M Najjar Journal: Metabolism Date: 2021-05-28 Impact factor: 13.934
Authors: Steven Hamley; Danielle Kloosterman; Tamara Duthie; Chiara Dalla Man; Roberto Visentin; Shaun A Mason; Teddy Ang; Ahrathy Selathurai; Gunveen Kaur; Maria G Morales-Scholz; Kirsten F Howlett; Greg M Kowalski; Christopher S Shaw; Clinton R Bruce Journal: Diabetologia Date: 2019-09-06 Impact factor: 10.122